NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non‑Oral Dosage Forms
The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy...
Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its New Drug Application...
Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties
Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement...
Zhongsheng Files China Trial Application to Expand Onradivir into High‑Risk Influenza A Patients, Broadening Its First‑in‑Class PB2 Inhibitor Franchise
Zhongsheng Pharmaceutical (SHE: 002317) announced that it has submitted a clinical trial application in China...
PegBio Signs R&D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long‑Acting Delivery for Metabolic Diseases
PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement...
Cutia Therapeutics’ CU‑20101 BLA Accepted by NMPA for Moderate to Severe Glabellar Lines, Advancing a Safer Botulinum Toxin Type A
Cutia Therapeutics (HKG: 2487) announced that the Biologics License Application (BLA) for CU‑20101 has been...
Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315; SHA: 688796) announced that it has signed a...
Haixi Pharma Completes Phase I of Oral HX9428 in nAMD with Visual Gains, Files IND for DME Phase IIa as FDA Fast Track Asset Expands
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced dual clinical progress updates for HX9428, its...
Hansoh’s HS‑20093 Risvutatug Rezetecan NDA Accepted by NMPA for Small Cell Lung Cancer After First Global Phase III OS Win for a B7‑H3 ADC
Hansoh Pharmaceutical (HKG: 3692) announced that the marketing authorization application for its independently developed HS‑20093...
Ocumension Completes Enrollment in China Phase III Trial of OT‑211 for Dry Eye Disease, Aligned with Global COMET Pivotal Program
Ocumension Therapeutics (HKG: 1477) announced that all subjects have been enrolled as scheduled in the...
Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.
Medtronic (NYSE: MDT) announced a strategic partnership with Cornerstone Robotics, including a strategic investment of...
HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL‑A830, Its First‑in‑Class KRAS ATTC Cancer Candidate
HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has...
Everest Medicines Wins NMPA Approval for Etripamil Nasal Spray Cardamyst in PSVT, Bringing ER‑Free Arrhythmia Care to Greater China
Everest Medicines (HKG: 1985) announced today that its etripamil nasal spray has received marketing approval...
NHSA Releases Version 3.0 DRG and DIP Grouping Schemes, Setting 2027 Deadline for China’s Disease-Based Payment Overhaul
China’s National Healthcare Security Administration (NHSA) officially released the Version 3.0 Grouping Scheme for Diagnosis-Related...
GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots
GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal...
NMPA Tightens Drug Traceability Rules, Mandating Full-Chain Code Scanning for MAHs and Distributors
The National Medical Products Administration (NMPA) issued the Announcement on Further Strengthening the Management of...
Allergan Aesthetics’ SKINVIVE by Juvéderm Wins NMPA Approval for Perioral Wrinkles, Backed by 93.4% POLSS Responder Rate
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that its SKINVIVE by Juvéderm, an injectable...
Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment
Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Beijing Centergate Technologies (SHE: 000931), has received...
Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis
Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1/-2 clinical trials of...
SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC
CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced that SYS6010, its epidermal growth factor receptor...